feeds

10.10.2018
2018

EMCDDA Director Alexis Goosdeel is paying an official visit to Cyprus today, where he is meeting with health and security officials. This is in line with the EMCDDA Strategy 2025, which aims to contribute to a healthier and more secure Europe.

09.10.2018
2018

This news item was published in the EMCDDA’s Cannabis drug policy news on 09.10.2018

2018

More than 9 000 lives were reported to be lost to drug overdoses in Europe (28 EU Member States, Turkey and Norway) in 2016, the latest reporting year, and this is an underestimate. Reducing drug-related deaths therefore remains a major challenge for public health policy. This analysis describes some of the factors that increase the risk of fatal and non-fatal overdoses and a number of interventions developed to prevent these events.

04.10.2018
2018

EMCDDA Director Alexis Goosdeel is participating this week in the EU-Western Balkans Ministerial Forum on Justice and Home Affairs, taking place from 4–5 October in Tirana.

01.10.2018
2018

EMCDDA Director Alexis Goosdeel is paying an official visit to Germany today at the invitation of the Federal Drug Commissioner Marlene Mortler. Discussions will centre on the further development of cooperation between Germany and the EMCDDA and the agency’s work priorities as outlined in Strategy 2025 and the Programming document 2018–20.

28.09.2018
2018

Today, the European Union has decided to subject two new synthetic opioids to control measures across the 28 Member States. The implementing decision of the Council of the EU (1), based on a proposal from the European Commission, was adopted in the final stage of the three-step legal procedure designed to respond to new psychoactive substances (NPS) that may pose public health and social threats (2)(3).

2018

This publication presents the data and findings of the risk assessment on N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]cyclopropanecarboxamide (cyclopropylfentanyl), carried out by the extended Scientific Committee of the EMCDDA on 21 March 2018. On the basis of the Risk Assessment Report — and on the initiative of the European Commission — on 27 September 2018, the Council decided that cyclopropylfentanyl should be subject to control measures across the Member States.

2018

This publication presents the data and findings of the risk assessment on 2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide (methoxyacetylfentanyl), carried out by the extended Scientific Committee of the EMCDDA on 21 March 2018. On the basis of the Risk Assessment Report — and on the initiative of the European Commission — on 27 September 2018, the Council decided that methoxyacetylfentanyl should be subject to control measures across the Member States.

25.09.2018
2018

Today, EMCDDA Director Alexis Goosdeel is addressing the 3rd Inter-sessional meeting of the United Nations Commission on Narcotic Drugs (CND) in Vienna. The four-day meeting will focus on: demand reduction; access to controlled substances for medical and scientific purposes; cross-cutting issues, such as human rights; and preparations for the next CND session (March 2019).

2018

In the 31 EU/EEA countries, more than 590 000 persons are held in a custodial facility on any given day. According to recent reviews of prison studies from EU countries, prison prevalence estimates for HCV ranged from 4.3 % to 86.3 %.

19.09.2018
2018

This week, the EMCDDA is participating in the 7th International Symposium on Hepatitis Care in Substance Users, organised by the International Network for Hepatitis in Substance Users (INHSU). The event, running from 19–21 September in Cascais, is exploring the latest advances in hepatitis C epidemiology, management and treatment of viral hepatitis among people who use drugs, with a specific focus on hepatitis C.

14.09.2018
2018

Director Alexis Goosdeel was in Belgium today where he met with Willy Demeyer, Mayor of Liège and currently President of the European Forum for Urban Security (EFUS). The purpose of the meeting was to explore possible cooperation between the EMCDDA and the forum.

2018

Partnership is a guiding principle for the EMCDDA as it works to increase its understanding of the external dimension of the drug phenomenon and its implications for public health and security in the EU and neighbouring countries. For more than a decade the EMCDDA has been working with countries outside the EU.

2018

This report is part of the EMCDDA-IPA5 project ‘Further preparation of the IPA beneficiaries for their participation with the European Monitoring Centre for Drugs and Drug Addiction’ funded by the European Commission. It provides a top-level overview of the drug phenomenon in Bosnia and Herzegovina, covering drug supply, use and public health problems as well as drug policy and responses. It has been produced with the financial assistance of the European Union.

2018

This report presents the key activities performed by the EMCDDA and Europol in 2017 and the results of the implementation of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances, including new psychoactive substances notified in 2017, Joint Reports produced, risk assessments conducted and public health-related alerts and advisories issued to the EU Early Warning System Network.

27.07.2018
2018

Every year, on 28 July, the World Health Organization (WHO) and partners mark World Hepatitis Day to increase awareness and understanding of viral hepatitis and the diseases it causes. The day unites patient organisations, governments, medical professionals, civil society, industry and the general public to boost the global profile of viral hepatitis. This year, the WHO will focus on the theme: ‘Test. Treat. Hepatitis’ affirming that timely testing and treatment of viral hepatitis B and C can save lives.

2018

Compared with the general public, people in prisons have a higher prevalence of infection with blood-borne viruses (BBVs) such as human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV). This is recognised as a major issue for the health of people in prisons, as well as the general population, because the majority of people who have been incarcerated will subsequently return to their communities.

2018

This evidence-based guidance aims to support the planning and implementation of effective programmes to prevent and control the transmission of infectious diseases in prison settings in the European region. It focuses on three high-burden blood-borne viruses (BBV) in the prison population, namely hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodefciency virus (HIV). The infections caused by these viruses are characterised by the same modes of blood-borne transmission and similar prevention and control interventions.

2018

This evidence-based guidance aims to support the planning and implementation of effective programmes to prevent and control the transmission of infectious diseases in prison settings in the European region. It focuses on three high-burden blood-borne viruses (BBV) in the prison population, namely hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodefciency virus (HIV). The infections caused by these viruses are characterised by the same modes of blood-borne transmission and similar prevention and control interventions.

23.07.2018
2018

People in prison experience a higher burden of communicable diseases such as hepatitis B (HBV), hepatitis C (HCV) and HIV often linked to a history of injecting drug use. In addition, incarceration can result in a higher risk of transmission of communicable diseases, due to factors such as overcrowding, poor healthcare facilities and delayed diagnosis.

17.07.2018
2018

EMCDDA Director Alexis Goosdeel today visited his new counterpart at Europol, Ms Catherine De Bolle in the first official meeting between the two heads of agencies.

2018

This publication presents the data and findings of the risk assessment on methyl 1-(2-phenylethyl)-4-[phenyl(propanoyl)amino]piperidine-4-carboxylate (carfentanil), carried out by the extended Scientific Committee of the EMCDDA on 7-8 November 2017. In March 2018, at its 61st regular session, the Commission on Narcotic Drugs (CND) decided to place carfentanil in Schedule I and Schedule IV of the Single Convention on Narcotic Drugs of 1961 based on a recommendation by the World Health Organization. This recommendation was substantially supported by European data provided by the EMCDDA.

2018

This publication presents the data and findings of the risk assessment on N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]oxolane-2-carboxamide (THF-F), carried out by the extended Scientific Committee of the EMCDDA on 7-8 November 2017. In March 2018, at its 61st regular session, the Commission on Narcotic Drugs (CND) decided to place tetrahydrofuranylfentanyl in Schedule I of the Single Convention on Narcotic Drugs of 1961 based on a recommendation by the World Health Organization. This recommendation was substantially supported by European data provided by the EMCDDA.

2018

This publication presents the data and findings of the risk assessment on N-(4-fluorophenyl)-2-methyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide (4F-iBF), carried out by the extended Scientific Committee of the EMCDDA on 7-8 November 2017. In March 2018, at its 61st regular session, the Commission on Narcotic Drugs (CND) decided to place 4F-iBF in Schedule I of the Single Convention on Narcotic Drugs of 1961 based on a recommendation by the World Health Organization. This recommendation was substantially supported by European data provided by the EMCDDA.

2018

This publication presents the data and findings of the risk assessment on methyl 2-{[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino}-3,3-dimethylbutanoate (5F-MDMB-PINACA), carried out by the extended Scientific Committee of the EMCDDA on 7-8 November 2017. In March 2018, at its 61st regular session, the Commission on Narcotic Drugs (CND) decided to place 5F-MDMB-PINACA in Schedule II of the Convention on Psychotropic Substances of 1971 based on a recommendation by the World Health Organization.

2018

This publication presents the data and findings of the risk assessment on N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA), carried out by the extended Scientific Committee of the EMCDDA on 7-8 November 2017. In March 2018, at its 61st regular session, the Commission on Narcotic Drugs (CND) decided to place AB-CHMINACA in Schedule II of the Convention on Psychotropic Substances of 1971 based on a recommendation by the World Health Organization.

2018

These are the EMCDDA's final annual accounts for the financial year 2017.

25.06.2018
2018

The seventh European drugs summer school (EDSS) — ‘Illicit drugs in Europe: demand, supply and public policies’ — opens today in Lisbon on the eve of International day against drug abuse and illicit trafficking.

2018

The General Report of Activities is an annual publication providing a detailed progress report of the EMCDDA’s activities over a 12-month period. It catalogues the Centre’s achievements in each area of its annual work programme. The report is a useful information source for all those seeking comprehensive information on the Centre and its work.

Loading